ClinicalTrials.gg
Not yet recruitingNCT07836673Updated Sep 23, 2026

Pre-Exercise Whey and Pea Protein in Adolescents With Type 1 Diabetes

An interventional study of low whey protein and moderate whey protein in T1D and T1DM, sponsored by University of Jordan. Not yet recruiting. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by University of Jordan · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether drinking whey protein or pea protein before exercise affects blood sugar levels and appetite in adolescents with type 1 diabetes. The study will also compare two different amounts of each type of protein.

The main questions this study aims to answer are:

  • Does drinking whey or pea protein before exercise affect blood sugar levels during and after moderate-intensity exercise?
  • Does the amount of protein consumed before exercise affect blood sugar levels?
  • Does whey or pea protein affect feelings of hunger, fullness, and satiety after exercise?

Researchers will compare four conditions: a low and moderate amount of whey protein and a low and moderate amount of pea protein. Each participant will complete all four conditions on separate study visits, allowing researchers to compare the effects within the same person.

Participants will:

  • Drink a protein beverage 45 min before exercise.
  • Complete 45 min moderate-intensity aerobic exercise under supervision.
  • Wear a continuous glucose monitor to measure blood sugar levels during and after exercise.
  • Report their feelings of hunger, fullness, and satiety at several times during the study.
  • Follow the same general food, physical activity, and diabetes management instructions before each study visit.

The study may help researchers understand whether the type and amount of protein consumed before exercise can help manage blood sugar levels and appetite around exercise in adolescents with type 1 diabetes.

02

Conditions studied

  • T1D
  • T1DM

Keywords

  • RCT
03

In context

Lead sponsor

University of Jordan is the lead sponsor of 131 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adolescents with T1D
  • Age: 12-18 years
  • T1D duration ≥ 1 year and \<10%
  • -for Age- z-score between -2 and +2
  • Able to complete 45 min moderate-intensity aerobic exercise
  • Using CGM or willing / able to wear study CGM
  • Using multiple daily injections

Exclusion criteria

Exclusion Criteria:

  • Medical comorbidities (celiac disease and thyroid disease),
  • Diabetes complications or gastroparesis,
  • milk protein allergy or eating disorders,
  • severe hypo/ diabetic ketoacidosis in the past 3 months
  • Age: \<12 or > 18 years
  • T1D duration \< 1 year or ≥10%
  • -for Age- z-score \< -2 or > +2
  • Unable to exercise safely (physical limitations, intellectual disability, autism, mental health conditions)
  • Not using/willing/able to use CGM
  • Using once daily/mixed insulin regimens
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    low whey protein

    Participants will consume a whey protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.

    Dietary Supplement: low whey protein

  • Experimental
    moderate whey protein

    Participants will consume a whey protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.

    Dietary Supplement: moderate whey protein

  • Experimental
    low pea protein

    Dietary Supplement: low Pea protein

  • Experimental
    moderate pea protein

    Dietary Supplement: Moderate Pea protein

Interventions

  • Dietary supplementlow whey protein

    Participants will consume a whey protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.

  • Dietary supplementmoderate whey protein

    Participants will consume a whey protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.

  • Dietary supplementlow Pea protein

    Participants will consume a pea protein beverage providing 0.25 g of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.

  • Dietary supplementModerate Pea protein

    Participants will consume a pea protein beverage providing the moderate prespecified dose of protein per kg of body weight, 45 minutes before moderate-intensity aerobic exercise. They will then complete the standardized exercise session under supervision. Glucose levels and appetite will be monitored during and after exercise.

06

What researchers measure

Primary outcomes

  1. Continuous blood glucose levels using CGM "FreeStyle Libre 2 sensor"

    Time frame: 3 hours

Secondary outcomes

  1. postprandial appetite using VAS

    Time frame: 3 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 23, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07836673
Responsible party
Sondos Al-Obaidi (PhD Student, Department of Nutrition and Food Technology, School of Agriculture, The University of Jordan, University of Jordan) — Principal investigator
First posted
Sep 23, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Sondos Alobaidi
Contact
sondosalobaidi@gmail.com
00962796329336

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion